News Novartis sets sights on new oral MS drug after phase 3 wins Novartis' oral BTK inhibitor remibrutinib has shown efficacy in a pair of phase 3 trials in multiple sclerosis, boosting its blockbuster credentials.
News As patents expire, fampridine is cleared for NHS use in MS Several years after other UK nations, people living with multiple sclerosis in England are finally able to get NHS treatment with fampridine.
R&D The changing multiple sclerosis landscape: Earlier diagnosis... Multiple sclerosis (MS) is undergoing a meaningful evolution in how it is understood, diagnosed, and managed.
News New data build case for Roche's oral BTK drug for MS Roche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns.
News After phase 3 clean sweep, Roche plans oral BTK filing in MS Roche is preparing to file for its oral multiple sclerosis drug fenebrutinib after a third phase 3 win, but could liver toxicity be a stumbling block?
News MSD and Mayo Clinic team up on AI drug discovery MSD has signed an industry-first deal with the Mayo Clinic that will allow it to use the health system's genomic and clinical data for drug discovery.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.